Biomarin Pharm trading higher by 7% on renewed M&A speculation following Betaville blog post, UBS tgt raise
- BMRN is trading higher by 7% this morning on renewed M&A speculation after Betaville blog, written by Ben Harrington (formerly of the UK's Telegraph), suggested Shire (SHPG) could be considering a merger with BMRN.
- {http://betaville123.blogspot.com/} Link to blog
- Subsequently, UBS has raised their price target on BMRN to $136 from $112